G Subjects: People with diabetes age 55 or more with previous history of cardiovascular disease, (coronary artery disease, stroke, peripheral vascular disease) or one cardiovascular risk factor (total cholesterol > 5.2 mmol/L, HDL cholesterol ≤ 0.9 mmol/L, hypertension, known microalbuminuria, current smoking status). G Exclusion criteria: Dipstick positive proteinuria, established diabetic nephropathy, severe renal disease, hyperkalaemia, congestive cardiac failure, low ejection fraction, (< 40%), uncontrolled hypertension, recent myocardial infarction or stroke. G Sites: Study conducted in 281 centres in 19 countries in North and South America and Europe, (Argentina, Austria, Belgium, Brazil, Canada, Denmark, Finland, France, Germany, Ireland, Italy, Mexico, Netherlands, Norway, Spain, Sweden, Switzerland, UK, USA). G Ethics: The HOPE Study protocol was approved locally by Ethics Committees and all subjects provided written informed consent. G Study design: The study was a 2 x 2 design with randomisation of subjects to 10 mg ramipril or placebo taken once-daily in the evening and 400 IU of Vitamin E or placebo daily. Follow-up visits at one month and then every six months. Duration of study was 4.5 years. G Treatment: The initial running period 2.5 mg ramipril for 7-10 days, continued into the study if creatinine concentration 200 µmols or lower and potassium < 5.5 mmol/L or lower. G Primary end point: Development of myocardial infarction, stroke, cardiovascular death. G Secondary end point: Total mortality admission to hospital for congestive cardiac failure, unstable angina, cardiovascular and revascularisation, overt nephropathy, heart failure, worsening angina, development of diabetes in subjects with no history of diabetes. G Other points: Patients were judged to have type 2 diabetes if they developed diabetes at age 30 years or older or were not taking insulin. Hypertension was defined as taking drugs to treat hypertension or blood pressure greater than 160/90 mmHg. MICRO-HOPE Substudy: Urinary albumin excretion measured at baseline one year end of study by the albumin and creatinine ratio in a first morning sample. Microalbuminuria defined as an albumin/creatinine ratio of 2 mg/mmol or higher in men and women. Overt nephropa- 
Results
G There were 9,541 participants in the HOPE Study of which 3,654 had diabetes (39.3%). The results are presented on this group alone. Some patients (n=77) participated in another substudy in which they only received 2.5 mg of ramipril and therefore the main data set is on the 3,577 subjects receiving 10 mg ramipril. G Mean age 65.4. 37% female. 56% previous history of hypertension. At the end of study 65% in the placebo group and 66% in the ramipril group were still taking the study drugs at the end of the 4.5 years of the study. G At four years 12% of the ramipril group and 15% of the placebo group were taking open label ACE inhibitors. G Reasons for stopping ramipril were cough, dizziness, angioedema, hypertension or clinical event. G The reasons for open label ACE inhibitor use in the placebo group were heart failure, proteinuria or hypertension.
Primary outcomes
G Combined primary outcome of myocardial infarction, stroke or cardiovascular death reduced by 25%, (ramipril 15.3% versus 19.8% placebo). G Myocardial infarction reduced 22%, (ramipril 10.2% versus 12.9% placebo). G Stroke reduced 33%, (ramipril 4.2% versus 6.1% placebo). G Cardiovascular death reduced 37%, (ramipril 6.2% versus placebo 9.7%).
Secondary outcomes
G Total mortality reduced 24% G Revascularisation reduced 17% G Overt nephropathy reduced 24% G Overt nephropathy, laser, therapy or dialysis reduced 16%.
Other outcomes
G Any heart failure reduced 20%. Transient ischaemic attacks reduced 26%. Worsening angina reduced 13%, (p=0.057). captopril. 12 However other studies have shown no distinct benefit of ACE inhibitors over beta blockers. 13 G The beneficial effect of ramipril was independent of whether the subject was already taking cardiovascular disease prevention agents such as aspirin, beta blockers or lipid-lowering agents. G With respect to microvascular outcomes, these results concord with the results of the Eurodiab Controlled trial of Lisinopril in insulin-dependent diabetes (EUCLID) nephropathy and the EUCLID retinopathy studies (using lisinopril 20 mg od), although these were type 1 diabetes mellitus patients only. Microvascular complications may have improved due to a beneficial effect on microvascular autoregulation. also has a licence for prevention of nephropathy in albuminuric patients with normotensive type 1 diabetes and hypertensive type 2 diabetes. G Rather than risk reductions from a health planning point of view, it is probably better to look at number needed to treat (NNT) to prevent an event. NNT is calculated as 100%/absolute % reduction in risk and denotes the number of subjects who must receive the study treatment to prevent one event. To illustrate its use, consider treatment A which reduces risk of Event X from 10% per year to 5% (also a risk reduction of 50%). The NNT is 100%/10-5 = 20 per year. Now consider treatment B which reduces risk of Event Y from 1% per year to 0.5% (also a risk reduction of 50% How to use ramipril 2.5 mg once a day for one week, 5 mg for three weeks and then 10 mg daily. In clinical practice ramipril is frequently given 5 mg od for one week followed by 10 mg od. Urea, potassium and creatinine levels should be checked after 2-4 weeks on ACE inhibition with the ACE inhibitor discontinued if the urea rises by 50% or more or if the creatinine rises by more than 20%. Attention to other drugs which worsen renal parameters (diuretics and other vasodilators) may allow continued use of ACE inhibitors.
Conclusion
At the average age of diagnosis of diabetes (55 years), the estimated life expectancy is reduced by seven years in women and five years in men, 80% of these premature deaths are due to cardiovascular disease. 6 All diabetes care programmes should aim to reduce cardiovascular disease by an aggressive strategy to decrease blood pressure to the target of 140/80 mmHg or lower, improve glycaemic control to a target HbA 1C of 7% or lower, lipid lowering (total cholesterol < 5 mmol/L, LDL < 3 mmol/L, HDL > 0.9 mmol/L), smoking cessation, aspirin treatment, together with due attention to healthy eating, exercise and weight reduction. The HOPE and MICRO-HOPE Study clearly shows the beneficial effect of adding an ACE inhibitor into this strategy (table 2). 
